AARTIPHARM Aarti Pharmalabs Q4 FY26 results (Jan–Mar 2026) and concall
Aarti Pharmalabs reported a mixed Q4 FY26, with revenue growth driven by strong performance in Xanthine and CDMO segments, which both achieved their highest ever quarterly revenues. However, profitability was impacted by higher operating costs, inventory issues, and a significant foreign exchange loss. The company is progressing with capacity expansions at Atali and Tarapur, and expects CDMO to lead growth in FY27, targeting 15-18% overall growth for the next 3-4 years.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 3.4%, net profit down 30.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 458 | 538 | 564 | 386 | 418 −9% | 432 −20% | 583 +3% |
| EBITDA | 94 | 129 | 146 | 93 | 74 −21% | 102 −21% | 113 −23% |
| Net profit | 55 | 74 | 88 | 50 | 28 −49% | 48 −35% | 61 −31% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
